Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
31 participants
INTERVENTIONAL
2023-03-01
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of the Gut Microbiome on Lean Mass and Physical Function in Older Adults
NCT02811445
Protein and Skeletal Muscle in Older Twins: Role of the Gut Microbiome
NCT04309292
Nutrient Support to Body Composition and Healthy Ageing
NCT02529124
C-Protein in Fatigue and Aging
NCT05926219
Lifestyle Modifications for the Treatment of Sarcopenic Obesity
NCT02379026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The gut microbiome and its metabolic products are involved in mechanisms that impact skeletal muscle mass, muscle composition, and physical function, which has been defined as the gut-muscle axis. For example, muscle mass and physical function are reduced in animals that do not have a microbiome (germ-free mice), and in antibiotic-treated mice, an intervention that reduces gut bacterial content. Investigating further, gut bacteria-derived metabolites affect muscle mass, muscle composition, and physical function in young and aged animals, including positive effects for the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate, and negative effects for indoxyl sulfate (IS) and para-cresol sulfate (PCS). Similarly, phenol sulfate (PS) and phenylacetylglutamine (PAG) are gut microbiome-derived metabolites that were associated with poor muscle composition and worse physical function in studies of older adult humans that were published by our group. Interestingly, higher colonic levels of SCFAs are associated with a lower pH, an important finding because growth of Enterobacteriaceae, a bacterial family that contains genes involved in the production of IS, PCS, PS, and PAG, is limited in an acidic environment and following exposure to physiological levels of SCFAs. Taken together, these data suggest that interventions aimed at increasing bacterial SCFA production may be an important approach for improving muscle-related measures in older adults.
Soluble fiber fermentation by gut bacteria results in the formation of acetate, propionate, and butyrate, and fecal SCFAs proportionally increase, whereas circulating levels of IS and PCS are reduced in response to high-soluble fiber diets. As a proof of concept, fecal and circulating levels of SCFAs, muscle mass, and aerobic exercise capacity were increased in young mice that were fed a relatively higher soluble fiber diet, but few studies have attempted this approach in older adult humans. When considering that fecal levels of SCFAs decrease during aging, whereas plasma levels of IS, PCS, PS, and PAG increase, these data collectively suggest that a high-soluble fiber diet may be an important approach for improving muscle-related measures in older adults humans. To test this hypothesis, older adults will be randomized to consume a high- or low-soluble fiber diet for 12-weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low-soluble fiber diet
Low-soluble fiber diet
12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
High-soluble fiber diet
High-soluble fiber diet
12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-soluble fiber diet
12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
High-soluble fiber diet
12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sedentary (Godin-Shepard Leisure Time Physical Activity Questionnaire score \< 10)
3. Non-smoking
4. Not already consuming a high-fiber diet (\> 22, 28 g/day for women, men)
5. Free of gastrointestinal disease (gastrointestinal cancer, inflammatory bowel disease, bariatric surgery, irritable bowel syndrome)
6. Fluent in English
7. Willing to attend three study visits (enrollment, baseline, and week-13)
8. Willing to consume an abundance of fruits, vegetables, nuts/seeds
9. Willing to consume an abundance of soluble fiber-rich foods (broccoli, brussels sprouts, flaxseeds sweetened with dates, lima beans, butternut squash, carrots, collard greens)
10. Willing to tolerate mild gastrointestinal discomfort (bloating, belly grumbling, flatulence). Note that all attempts will be made to replace foods that may trigger these issues.
11. Willing to not consume antibiotics during the 13-week study
12. Willing to not schedule a colonoscopy during the 13-week study
Exclusion Criteria
2. Unwilling to only consume the provided food (unsweetened tea and/or black coffee are allowed)
3. Food allergies related to foods that are included in the study
4. Chewing problems
5. Unwilling to wear a daily step counter (pedometer)
6. Unwilling to complete a daily questionnaire that will assess gastrointestinal comfort
7. Malnutrition (BMI \< 18.5 kg/m2)
8. Use of supplemental probiotics or antibiotics, participation in an investigational drug evaluation, or a recent change in habitual medication use within the 1 month-period prior to the screening visit
9. \> 5% weight loss or weight gain within the past 6-months
10. A recent history of alcohol abuse (within the past 5 years)
11. A history of any significant injury or surgery that currently affects physical functioning and ability to perform physical function testing
12. Treatment with immunosuppressive drugs
13. A prior diagnosis of organ failure (heart, liver, renal, respiratory)
14. Diabetes mellitus (type 1, or type 2 with insulin therapy)
15. Chronic kidney disease (eGFR ≤ 30 mL/min/1.73 m2)
16. Overt disease (cancer, dementia, cardiovascular disease)
17. Chronic use of anti-inflammatory medication (corticosteroids)
18. Already enrolled in another research study
19. Active infection, including Tuberculosis , HIV, malaria, hepatitis, shingles, Methicillin-Resistant Staphylococcus Aureus (MRSA), SARS-CoV-2
20. Any major illness or condition that may interfere with study outcomes at the discretion of the study physician
21. Won't remain in Boston for the 13-week study duration
22. Unwilling to complete a daily checklist aimed at quantifying the amount of food eaten on the study diet
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tufts University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jennifer Lee
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael S Lustgarten, PhD
Role: STUDY_DIRECTOR
Scientist II, NEPS Laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jean Mayer Human Nutrition Research Center on Aging at Tufts University
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GRANT13386865
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.